Manufacturers Look to Vaccines for Growth and Innovation - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Manufacturers Look to Vaccines for Growth and Innovation
Vaccine R&D is surging, but continues to raise manufacturing and regulatory challenges.


Pharmaceutical Technology
Volume 34, Issue 2, pp. 30-37

Regulatory responses

The desire to develop more vaccines to meet global health needs has highlighted vaccine regulation in the US and abroad. Although FDA streamlined its testing and data requirements for H1N1-vaccine candidates, manufacturers would like to see a more coordinated international approval process. The WHO vaccine prequalification process takes approximately 18 months, in addition to all the work involved in licensing a product with FDA or European authorities.

FDA is working closely with WHO to improve this process. One idea is to couple US or European Union licensure of a new vaccine with WHO prequalification to spur world access to the new product, explained acting director of FDA's Center for Biologics Evaluation and Research Karen Midthun at a November conference on global vaccine development sponsored by the Drug Information Association. FDA is providing advice on clinical-trial issues for global vaccine development, helping to assess new technology for vaccine manufacture, and working with WHO to help build regulatory capacity in developing countries.

"We are poised for a transformation in how we produce and use influenza vaccine," Goodman said, noting that these efforts align with FDA's goal to strengthen the agency's scientific infrastructure, particularly for novel technologies and products that can improve public health. FDA is, for example, looking to use molecular biology to improve the way the agency assesses new influenza-virus strains and to test for potency, purity, and sterility in lot release.

A December 2009 report from the Institute of Medicine (IOM) urges a more coordinated US approach to vaccine development and safety monitoring under a strengthened National Vaccine Program Office. The program would target support for vaccine R&D to untreated diseases, focus more attention on vaccine safety issues, expand healthcare plan coverage for all recommended vaccines and better address fears and misinformation about vaccine effectiveness and safety.

Jill Wechsler is Pharmaceutical Technology's Washington editor, 7715 Rocton Ave., Chevy Chase, MD 20815, tel. 301.656.4634,


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: Pharmaceutical Technology,
Click here